Journal of the American Chemical Society
Page 4 of 5
Viswambharan, B.; Gori, D.; Kouklovsky, C.; Alezra, V. J. Org.
asymmetric cyclization of substrate 7g possessing a tertꢀ
butyl group at C(6) and a methyl group at C(3) (entry
11). Treatment of 7g with TMS(tꢀBu)NLi in THF at –78
˚C gave 8g in 91% ee and 89% yield without formation
of the product from βꢀelimination. These results indicate
that both a bulky substituent at C(6) and an additional
substituent at C(3) are indispensible for highly enantiꢀ
oselective sixꢀmembered cyclization. The absolute conꢀ
figuration of 8e was determined to be R by the PGME
method14 (see Supporting Information). This indicates
that the sixꢀmembered cyclization of 7e proceeds with
inversion of configuration.
Chem. 2012, 77, 8797ꢀ8801. (e) Mai, T. T.; Branca, M.; Gori, D.;
Guillot, R.; Kouklovsky, C.; Alezra, V. Angew. Chem. Int. Ed. 2012,
51, 4981ꢀ4984. (f) Fletcher, S. P.; Solá, J.; Holt, D.; Brown, R. A.;
Clayden, J. Beilstein J. Org. Chem. 2011, 7, 1304ꢀ1309. (g) Branca,
M.; Pena, S.; Guillot, R.; Gori, D.; Alezra, V.; Kouklovsky, C. J. Am.
Chem. Soc. 2009, 131, 10711ꢀ10718. (h) Kolaczkowski, L.; Barnes,
D. M. Org. Lett. 2007, 9, 3029ꢀ3032. (i) MacQuarrieꢀHunter, S.; Carꢀ
lier, P. R. Org. Lett. 2005, 7, 5305ꢀ5308. (j) GeronaꢀNavarro, G.;
Bonache, M. A.; Hernz, R.; GarcíaꢀLópez, M. T.; GonzálezꢀMuñiz, R.
J. Org. Chem. 2001, 66, 3538ꢀ3547.
1
2
3
4
5
6
7
8
(3) Kawabata, T.; Yahiro, K.; Fuji, K. J. Am. Chem. Soc. 1991,
114, 9694ꢀ9696.
(4) Asymmetric alkylation of configurationally stable αoxyꢀ
carbanions has been extensively developed. See: (a) Still, W. C.;
Streekumar, C. J. Am. Chem. Soc. 1980, 102, 1201ꢀ1202. (b) Hoppe,
D.; Hense, T. Angew. Chem. Int. Ed. 1997, 36, 2282ꢀ2316. (c) Baek,
P.; Basu, A.; Gallagher, D. J.; Pack, Y. S.; Thayumanavan, S. Acc.
Chem. Res. 1996, 29, 552ꢀ560.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(5) Configurationally stable biaryl ethers have been developed.
See: (a) Fuji, K.; Oka, T.; Kawabata, T.; Kinoshita, T.; Tetrahedron
Lett. 1998, 39, 1373ꢀ1374. (b) Betson, M. S.; Clayden, J.; Worrall, C.
P. Peace, S. Angew. Chem. Int. Ed. 2006, 45, 5803ꢀ5807.
(6) Dramatic temperature effects in alkylation reactions of benzoꢀ
diazepine enolates via memory of chirality has been reported. See:
reference 2i and Carlier, P. R.; Zhao, H.; MacQarrieꢀHunter S. L.;
DeGuzman, J. C.; Hsu, D. C. J. Am. Chem. Soc. 2006, 128, 15215ꢀ
15220.
(7) Uozumi, Y.; Kato, K.; Hayashi, T. J. Am. Chem. Soc. 1997,
119, 5063ꢀ5064.
In conclusion, we have developed a novel method for
asymmetric synthesis via shortꢀlived axially chiral enoꢀ
lates based on the restricted rotation of the CꢀO bond.
This method provides a unique entry to chiral cyclic
ethers with a tetrasubstituted chiral center. These comꢀ
pounds were prepared via asymmetric CꢀC bond forꢀ
mation by the present method, while they have usually
been constructed via asymmetric CꢀO bond formation.15
(8) The racemization barrier of the chiral sodium enolate derived
from 2c could be quite different from the rotational barrier of 6 beꢀ
cause of the aggregation of the sodium enolate. However, we previꢀ
ously observed that the racemization barrier of a chiral potassium
enolate with a CꢀN axis generated from an amino acid derivative,
which was determined experimentally by periodic quenching of the
enolate, was found to be comparable with the rotational barrier of the
CꢀN axis of the the corresponding silyl ketene acetal, which was deꢀ
termined by VNMR measurement. See reference 1a.
(9) Chiral enolate structure C(2c) based on the restricted rotation of
the C(1’)ꢀO bond was shown tentatively. While that based on the
restricted rotation of the C(1)ꢀO bond cannot to be excluded, we preꢀ
fer the former because asymmetric cyclization of 2 either with a
smaller (Me) or a larger (Me3Si) substituent at C(6) than CH2Br at
C(2) gave the product with the same absolute configuration (Table 1).
(10) A conformational search for 2c was performed by a molecular
modeling search (MCMM 50,000 steps) with an OPLS 2005 force
field using MacroModel (V. 9.0). Conformer 2c-II was suggested to
be 5.8 kcal/mol less stable than the most stable conformer 2c-I. For
details, see Supporting Information.
(11) The importance of the chelation may be suggested by the deꢀ
crease in the enantioselectivity of the asymmetric cyclization of 2b in
the presence of 15ꢀcrownꢀ5. Treatment of 2b under the conditions
identical to those in entry 6 of Table 1, except for the addition of 15ꢀ
crownꢀ5 (3.0 equivalents), gave 3b in 30% ee and 72% yield. The
similar chelating effect affecting stereochemistry of enolate alkylation
was reported. See: Willimas, R. M.; Glinka, T.; Kwast, E. J. Am.
Chem. Soc. 1988, 110, 5927ꢀ5929.
Readily available and abundant Lꢀethyl lactate is used
not only as a functionalized carbon resource but also as a
chiral source for the construction of chiral benzofuran
and chroman derivatives with tetrasubstituted carbon,
which frequently appear in biologically active prodꢀ
ucts.16,17
ASSOCIATED CONTENT
Supporting Information. Experimental procedures and
spectroscopic data for all new compounds. Variableꢀ
temperature NMR of 6. This material is available free of
AUTHOR INFORMATION
Corresponding Author
kawabata@scl.kyotoꢀu.ac.jp
(12) The electrophilic center (C(2)ꢀCH2ꢀCH2ꢀI) of the chiral enoꢀ
lates generated from 7dꢀg may be in close proximity to the nucleoꢀ
philic enolate moiety due to the buttressing effect of the substituent at
C(3), which facilitates intramolecular alkylation before complete
racemization of the chiral enolate takes place. For the detailed discusꢀ
sion, see Supporting Information (Scheme SIꢀ1). The rate acceleration
by the buttressing effect of the ortho substituent in carbene CꢀH insertion
has been reported. See: Tomioka, H.; Kimoto, K.; Murata, H.; Izawa, Y. J.
C. S. Perkin I, 1991, 471ꢀ477.
ACKNOWLEDGMENT
We thank Professor Kiyosei Takasu, Faculty of Pharmaceuꢀ
tical Sciences, Kyoto University, for the valuable discusꢀ
sion. This work was partially supported by a grantꢀinꢀaid
for Young Scientists (B) from the Ministry of Education,
Culture, Sports, Science and Technology, Japan.
(13) Xie, L.; Isenberger, K. M.; Held, G.; Dahl, L. M. J. Org.
Chem. 1997, 62, 7516ꢀ7519.
(14) Yabuuchi, T.; Kusumi, T. J. Org. Chem. 2000, 65, 397ꢀ404.
(15) For examples of methods for the synthesis of benzofuran and
chroman derivatives via CꢀO bond formation, see (a) reference 7. (b)
Uozumi, Y.; Kyota, H. Kato, K.; Ogasawara, M.; Hayashi, T. J. Org.
Chem. 1999, 64, 1620ꢀ1625. (c) Torraca, K. E.; Kuwabe, S.; Buchꢀ
wald, S. L. J. Am. Chem. Soc. 2000, 122, 12907ꢀ12908. (d) Trost, B.
M.; Shen, H. C.; Dong, L.; Surivet, J.ꢀP. J. Am. Chem. Soc. 2003, 125,
9276ꢀ9277.
REFERENCES
(1) For selected references, see: (a) Kawabata, T.; Suzuki, H.; Naꢀ
gae, Y.; Fuji, K. Angew. Chem. Int. Ed. 2000, 39, 2155ꢀ2157. (b)
Kawabata, T.; Kawakami, S.; Majumdar, S. J. Am. Chem. Soc. 2003,
125, 13012ꢀ13013. (c) Kawabata, T.; Matsuda, S.; Kawakami, S.;
Monguchi, D.; Moriyama, K. J. Am. Chem. Soc. 2006, 128, 15394ꢀ
15395. (d) Kawabata, T.; Moriyama, K.; Kawakami, S.; Tsubaki, K.
J. Am. Chem. Soc. 2008, 130, 4153ꢀ4157. (e) Watanabe, H.; Yoshiꢀ
mura, T.; Kawakami, S.; Sasamori, T.; Tokitoh, N.; Kawabata, T.
Chem. Commun. 2012, 48, 5346ꢀ5348.
(2) For reviews on asymmetric synthesis via axially chiral enolates
with a dynamic nature, see: (a) Zhao, H.; Hsu, D. C.; Carlier, P. R.
Synthesis 2005, 1ꢀ16. (b) Kawabata, T. ACS Symposium Series 1009.
“Asymmetric Synthesis and Application of αꢀAmino Acids”. 2009,
pp. 31ꢀ56. (c) Carlier, P. R.; Hsu, D. C.; Bryson, S. A.; Topics in
Stereochemistry; Denmark, S. E., Ed.; John Wiley & Sons: New
York, 2010; Vol. 26, pp53ꢀ92. For recent reports on the asymmetric
reactions via axially chiral enolates, see: (d) Mai, T. T.;
(16) For examples of biologically active benzofuran derivatives
with tetrasubstituted carbon, see: (a) Mayer, G.; Taberner, P. V. Eur.
J. Pharmacol. 2002, 454, 95ꢀ102. (b) Cohen, J. L.; Limon, A.; Miledi,
R.; Chamberlin, A. R. Bioorg. Med. Chem. Lett. 2006, 16, 2189ꢀ2194.
(17) For examples of biologically active chroman derivatives with
tetrasubstituted carbon at C(2), see: (a) Grisar, J. M.; Petty, M. A.;
Bolkenius, F. N.; Dow, J.; Wagner, J.; Wagner, E. R.; Haegele, K. D.;
De Jong, W. J. Med. Chem. 1991, 34, 257ꢀ260. (b) Grisar, J. M.;
Marciniak, G.; Bolkenius, F. N.; VerneꢀMismer, J.; Wagner, J.; Wagꢀ
ner, E. R. J. Med. Chem. 1995, 38, 2880ꢀ2886.
ACS Paragon Plus Environment